EHA Congress | Conferences

Prolonged Reponses Following ASCT and Standard Consolidation/Induction With Daratumumab Maintenance

June 20, 2021

Benefit was seen with daratumumab maintenance therapy for patients with newly diagnosed multiple myeloma who received autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone.

Promising Responses Seen With Intensified Daratumumab Induction in Ultra High–Risk Multiple Myeloma

June 19, 2021

Intensified induction therapy with daratumumab plus cyclophosphamide, bortezomib, lenalidomide, and dexamethasone followed by bortezomib-augmented autologous stem cell transplant resulting in deep remissions or patients with ultra¬ high-risk multiple myeloma or primary plasma cell leukemia.

Deep Remission Achieved with Daratumumab Plus CyBorD Followed by Daratumumab Maintenance for Multiple Myeloma

June 19, 2021

Daratumumab plus cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses in patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status.

Luspatercept Leads to Hemoglobin Increase in Patients With Non-Transfusion–Dependent Beta-Thalassemia

June 15, 2021

Without requiring red blood cell transfusions, luspatercept-aamt led to a mean increase in hemoglobin from baseline levels in 77.1% of patients compared with in 0% treated with placebo in patients with non-transfusion–dependent β-thalassemia in the phase 2 BEYOND trial, according to a presentation during the European Hematology Association 2021 Virtual Congress.